| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bb54e0dd9573d32316a490e981fe014f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a01d7935508cbe002beb151d4efde669 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S436-811
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2821
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4711
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-543
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-542
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-537
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 |
| filingDate |
2004-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c4e5c0beeb64080da58e8bed5322e2a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5998bda4857f37b9d03f423f3badf47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68c9c4d0d9966da2afb1e17ff1590b02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ecd64b7372a5d553ee52f9f374eaa9a |
| publicationDate |
2005-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2005069968-A1 |
| titleOfInvention |
Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-b peptide (x->41) and tau |
| abstract |
This invention provides methods useful in aiding in the diagnosis of Alzheimer's disease. The methods involve measuring the amount of amyloid-β peptide (x-≧41) in the cerebrospinal fluid of a patient. High levels of the peptide generally are inconsistent with a diagnosis of Alzheimer's. Low levels of the peptide are consistent with the disease and, with other tests, can provide a positive diagnosis. Other methods involve measuring the amounts of both Aβ(x-≧41) and tau. Low levels of Aβ(x-≧41) and high levels of tau are a positive indicator of Alzheimer's disease, while high levels of Aβ(x-≧41) and low levels of tau are a negative indication of Alzheimer's disease. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7811769-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11275092-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7700309-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7427392-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004265920-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10393759-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009123952-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004253643-A1 |
| priorityDate |
1994-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |